Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrexafungerp vs. Fluconazole in Vulvovaginal Candidiasis
NCT02679456Phase 2Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Nov 2015
- Primary completion
- Aug 2016
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ibrexafungerp in vulvovaginal candidiasis (VVC), sponsored by SCYNEXIS, Inc. Started Nov 2015; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT02679456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02679456.